Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation.

Biochemical and biophysical research communications - 27 May 2005

Asano Takayuki, Yao Yixin, Zhu Jijiang, Li Donghui, Abbruzzese James L, Reddy Shrikanth A

Abstract excerpt

We present immunohistochemical evidence that the mTOR/p70s6k pathway is activated in pancreatic tumors and show that the mTOR inhibitor and rapamycin analog CCI-779 potently suppresses the proliferation of pancreatic cancer cells. Consistent with a recent study, CCI-779 increased c-Jun phosphorylation (Ser63) in a dose- and time-dependent manner, and induced apoptosis in p53-defective BxPC-3 cells. In contrast to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Apoptosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pancreatic Neoplasms

Share to Protein Kinases

Share to Proto-Oncogene Proteins c-jun

Share to Sirolimus

Share to TOR Serine-Threonine Kinases

Share to Tumor Cells, Cultured

Source

Identifiers

PMID: 15845392
DOI: 10.1016/j.bbrc.2005.03.166

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation.PMID 15845392Read ↗

Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancerSemantic proximity Read ↗

The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy.Semantic proximity Read ↗

Mechanisms of resistance to rapamycins.Semantic proximity Read ↗

Radiosensitization effect of STI-571 on pancreatic cancer cells in vitro.Semantic proximity Read ↗

Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1).Semantic proximity Read ↗

MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.Semantic proximity Read ↗

Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignanciesSemantic proximity Read ↗

Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.Semantic proximity Read ↗

Calcitriol enhances gemcitabine antitumor activity in vitro and in vivo by promoting apoptosis in a human pancreatic carcinoma model systemSemantic proximity Read ↗

Pegylated IFN-α suppresses hepatitis C virus by promoting the DAPK-mTOR pathway.Semantic proximity Read ↗

Rapamycin protects against dominant negative-HNF1A-induced apoptosis in INS-1 cells.Semantic proximity Read ↗

Inhibition of p70 S6 kinase (S6K1) activity by A77 1726, the active metabolite of leflunomide, induces autophagy through TAK1-mediated AMPK and JNK activation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.